Purchase this article with an account.
C. S. Cho, J. Kim, K.-W. Kim, Y. Yu, J. Kim; Effect of Anti-Vascular Endothelial Growth Factor Antibody on the Differentiation of Retinoblastoma Cells. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2663.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate whether anti-vascular endothelial growth factor (VEGF) antibody affects the differentiation of retinoblastoma cells
Human retinoblastoma cells, SNUOT-Rb1, were differentiated by treatment of 0.1% bovine serum albumin (BSA), and then treated by anti-VEGF antibody (Bevaxizumab) for 48 hours. To determine the differentiation of SNUOT-Rb1, the neurotrophin receptors (Trk A, Trk B) and the neuronal differentiation markers (Shank1, 2) were detected by Western blot analysis and reverse transcriptase-polymerase chain reaction (RT-PCR), respectively. Furthermore, extracellular signal-regulated kinases 1 and 2 (ERK 1/2) phosphorylation was also detected.
Treatment of anti-VEGF antibody did not affect to cell viability, but attenuated neurite outgrowth of 0.1% BSA treated-retinoblastoma cells. mRNA of Shank 1 and 2 were decreased by anti-VEGF antibody treatment, which might be mediated by inhibition of ERK 1/2 phosphorylation. Furthermore, Trk A expression was decreased by anti-VEGF antibody treatment.
Anti-VEGF antibody treatment might inhibit the differentiation of retinoblastoma cells. Therefore, anti-VEGF antibody should be careful to treat to the developing eyes, because of the effect of anti-VEGF antibody on neuronal differentiation.
This PDF is available to Subscribers Only